News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Opko Health, Inc. Announces Presentation Of Data On Long-Acting Oxyntomodulin At Diabetes Conference


4/23/2014 6:56:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OPKO Health, Inc. (NYSE: OPK) today announced that it will present data on its long acting oxyntomodulin (MOD-6030) product on April 25, 2014 at the 7th Diabetes Drug Discovery and Development Conference being held in Cambridge, MA. Company scientists will make an oral presentation discussing MOD-6030, the company's long-acting GLP-1 and Glucagon dual agonist with potential for the treatment of type 2 diabetes and obesity. Pre-clinical data shows the drug induced a marked weight loss and food intake inhibition in both animal models which were superior compared to those with bi-daily injections of native OXM and to bi-daily injections of existing marketed drugs.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES